Analysis of survival at transplantation day 200 among patients in the current trial and in the previous randomized, placebo-controlled trial of oral BDP
| . | Current trial . | Previous trial11 . | ||
|---|---|---|---|---|
| Placebo . | BDP . | Placebo . | BDP . | |
| No. randomized | 67 | 62 | 29 | 31 |
| No. who died (%) | 16 (24) | 5 (8) | 6 (21) | 3 (10) |
| Death with infection,* no. (%) | 9 (13) | 3 (5) | 5 (17) | 2 (6) |
| Death with relapse,* no. (%) | 9 (13) | 3 (5) | 4 (14) | 1 (3) |
| . | Current trial . | Previous trial11 . | ||
|---|---|---|---|---|
| Placebo . | BDP . | Placebo . | BDP . | |
| No. randomized | 67 | 62 | 29 | 31 |
| No. who died (%) | 16 (24) | 5 (8) | 6 (21) | 3 (10) |
| Death with infection,* no. (%) | 9 (13) | 3 (5) | 5 (17) | 2 (6) |
| Death with relapse,* no. (%) | 9 (13) | 3 (5) | 4 (14) | 1 (3) |
The hazard ratio (95% confidence interval) for the current trial was 0.33 (0.12-0.89); for the previous trial, 0.47 (0.12-1.87).
Some patients died with both infection and relapse of their underlying malignancy.